| Document Date: 2014-02-24 14:34:27
Open Document File Size: 115,43 KBShare Result on Facebook
City South San Francisco / / Company Calithera Biosciences Inc. / Calithera Biosciences Calithera Biosciences Inc. / / Country United States / / Event FDA Phase / / IndustryTerm biopharmaceutical company discovering / / MedicalCondition solid and hematologic tumor / tumor / cancer / mesothelioma / multiple myeloma / lymphoma / non-small cell lung cancer / triple-negative breast cancer / glutamine-requiring cancer / renal cell carcinoma / advanced solid tumors / advanced multiple myeloma / specific tumor / diffuse large B-cell lymphoma / both solid and hematological tumor / acute leukemias / hematological cancers / / Organization American Society of Hematology / / Person Susan M. Molineaux / / Position Chief Executive Officer and President / / Product CB-839 / to / First-in-Class Glutaminase Inhibitor / / ProvinceOrState California / / Technology pharmacokinetics / pharmacodynamics / apoptosis / / URL www.calithera.com / /
SocialTag |
First patient dosed on CB-839 press release FINAL[removed]